Many people prescribed Rybelsus (semaglutide) for type 2 diabetes wonder whether this medication might affect their emotional wellbeing. Whilst mood swings are not listed as a recognised side effect in official UK prescribing information, some individuals report experiencing mood changes during treatment. Understanding the potential indirect factors—such as blood glucose fluctuations, gastrointestinal symptoms, and the psychological impact of weight loss—can help you manage your diabetes effectively whilst maintaining good mental health. This article explores the relationship between Rybelsus and mood, offering practical guidance on when to seek medical advice.
Quick Answer: Mood swings are not listed as a recognised side effect of Rybelsus in UK prescribing information, though some individuals report mood changes during treatment.
Rybelsus (semaglutide) is an oral medication licensed in the UK for the treatment of type 2 diabetes mellitus in adults. It belongs to a class of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists. Rybelsus is typically prescribed when diet and exercise alone have not achieved adequate glycaemic control, and it may be used alongside other glucose-lowering therapies such as metformin.
The active ingredient, semaglutide, works by mimicking the action of a naturally occurring hormone called GLP-1. This hormone is released by the intestines in response to food intake and plays several important roles in glucose regulation. Semaglutide stimulates insulin secretion from the pancreas when blood glucose levels are elevated, helping to lower blood sugar after meals. It also suppresses glucagon release, a hormone that raises blood glucose, and slows gastric emptying, which reduces the rate at which glucose enters the bloodstream.
Additionally, semaglutide acts on receptors in the brain that regulate appetite, often leading to reduced food intake and weight loss—a beneficial effect for many people with type 2 diabetes who are overweight. While weight loss is frequently observed in clinical trials, it's important to note that Rybelsus is not licensed for weight management.
Rybelsus is taken once daily on an empty stomach with up to 120 ml of water. It should be swallowed whole (not split or crushed) at least 30 minutes before the first food, drink, or other oral medications of the day, to ensure optimal absorption. Treatment typically starts with a 3 mg dose for 30 days, then increases to 7 mg daily, with a possible further increase to 14 mg if needed for glycaemic control.
The risk of hypoglycaemia (low blood sugar) with Rybelsus alone is low, but increases when combined with sulfonylureas or insulin.
The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) have approved Rybelsus based on clinical trial evidence demonstrating its efficacy in improving glycaemic control in type 2 diabetes.
Mood swings are not listed as a common or recognised side effect of Rybelsus in the official Summary of Product Characteristics (SmPC) or patient information leaflet. However, some individuals report experiencing changes in mood or emotional wellbeing whilst taking GLP-1 receptor agonists, and it is important to understand the potential contributing factors.
There is no official direct pharmacological link between semaglutide and mood disturbances. GLP-1 receptors are present in various brain regions, including areas involved in appetite regulation, but current evidence does not establish a clear mechanism by which Rybelsus would directly alter mood or cause mood swings. That said, several indirect factors may contribute to emotional changes during treatment.
Blood glucose fluctuations can significantly affect mood and energy levels. As Rybelsus lowers blood sugar, individuals may experience symptoms of hypoglycaemia (low blood sugar)—particularly if taking other glucose-lowering medications such as sulfonylureas or insulin—which can manifest as irritability, anxiety, confusion, or mood changes. Conversely, improved glycaemic control may enhance mood and cognitive function over time.
Gastrointestinal side effects are common with Rybelsus, including nausea, vomiting, diarrhoea, and reduced appetite. These symptoms, especially if persistent, can affect quality of life, sleep, and nutritional intake, potentially contributing to feelings of low mood, fatigue, or irritability.
Weight loss, while often a desired outcome, can sometimes be accompanied by psychological adjustment challenges. Changes in body image, eating patterns, or energy levels may influence emotional wellbeing. Additionally, individuals with pre-existing mental health conditions or a history of mood disorders may be more sensitive to any physiological changes associated with new medication.
It is also important to consider that type 2 diabetes itself is associated with higher rates of depression and anxiety, and mood changes may reflect the underlying condition rather than the medication.
The MHRA and EMA have reviewed reports of suicidal thoughts and self-harm behaviours in patients taking GLP-1 receptor agonists. Current evidence does not support a causal link between these medications and suicidal ideation, but regulatory authorities continue to monitor the situation. A holistic assessment is therefore essential when evaluating mood symptoms during Rybelsus treatment.
Mounjaro® is the most innovative GLP-1 medication proven to dramatically curb appetite, hunger, and cravings to help professional men achieve substantial weight loss.
Start Here
Wegovy® is a weekly injectable GLP-1 medication with proven effectiveness in reducing appetite, hunger, and cravings to help busy professionals lose significant weight.
Start HereIf you experience mood changes whilst taking Rybelsus, there are several practical strategies that may help manage these symptoms and support your overall wellbeing.
Monitor blood glucose levels regularly, especially during the first few weeks of treatment or after dose adjustments. Keeping a diary of your blood sugar readings alongside any mood symptoms can help identify patterns. If you notice mood changes coinciding with low blood glucose, discuss this with your GP or diabetes specialist nurse. They may need to adjust your medication regimen to reduce the risk of hypoglycaemia.
Address gastrointestinal side effects proactively. Nausea and other digestive symptoms often improve over time as your body adjusts to Rybelsus. Eating smaller, more frequent meals, avoiding high-fat or spicy foods, and staying well-hydrated can help. If symptoms are severe or persistent, your healthcare provider may recommend anti-nausea medication or a temporary dose reduction—do not self-medicate without clinical guidance.
Maintain a balanced diet and regular eating schedule. Adequate nutrition is essential for both physical and mental health. Even if your appetite is reduced, ensure you consume sufficient calories, protein, vitamins, and minerals. A registered dietitian with expertise in diabetes can provide tailored advice.
Prioritise sleep, physical activity, and stress management. Regular exercise has proven benefits for mood regulation and glycaemic control. Aim for at least 150 minutes of moderate-intensity activity per week, as recommended by the UK Chief Medical Officers and NHS guidelines. Good sleep hygiene and stress-reduction techniques such as mindfulness or relaxation exercises can also support emotional wellbeing.
Stay connected with your healthcare team. Regular follow-up appointments allow for ongoing assessment of both your diabetes control and overall health. Be open about any mood changes, as your GP can help determine whether these are related to Rybelsus, your diabetes, or other factors. They may also screen for depression or anxiety using validated tools.
Consider psychological support if mood symptoms are affecting your daily life. Talking therapies such as cognitive behavioural therapy (CBT) are effective for managing mood disorders and are available through NHS Talking Therapies services (self-referral or GP referral) or private providers.
Whilst mild, transient mood changes may not require immediate medical attention, certain symptoms warrant prompt consultation with your GP or healthcare provider.
Seek medical advice if you experience:
Persistent or worsening low mood lasting more than two weeks, particularly if accompanied by loss of interest in activities you usually enjoy, feelings of hopelessness, or thoughts of self-harm
Severe anxiety or panic attacks that interfere with daily functioning
Significant changes in sleep patterns, such as insomnia or excessive sleeping
Marked irritability or anger that is out of character or affecting your relationships
Symptoms of hypoglycaemia (shakiness, sweating, confusion, rapid heartbeat) occurring frequently, as these require medication adjustment. Always carry fast-acting glucose with you and contact your diabetes team for recurrent episodes
Severe or persistent gastrointestinal symptoms that prevent adequate nutrition or hydration
Any thoughts of self-harm or suicide—this requires urgent medical attention. If you feel you may act on suicidal thoughts or are in immediate danger, call 999 or go directly to A&E. Alternatively, contact your GP immediately, call NHS 111, or contact the Samaritans (116 123) who provide 24-hour confidential support.
Do not stop taking Rybelsus abruptly without consulting your healthcare provider, as this may affect your diabetes control. Your GP can assess whether your symptoms are related to the medication and discuss alternative treatment options if necessary. They may also investigate other potential causes of mood changes, such as thyroid dysfunction, vitamin deficiencies, or undiagnosed mental health conditions.
If you have a history of depression, anxiety, or other mental health conditions, inform your prescriber before starting Rybelsus. Regular monitoring may be appropriate to ensure your emotional wellbeing is maintained throughout treatment.
If you suspect Rybelsus may be causing side effects, including mood changes, you can report this through the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app).
Remember that effective diabetes management involves treating the whole person, not just blood glucose levels. Your healthcare team is there to support both your physical and mental health, and open communication about any concerns is essential for optimal care.
Mood swings are not listed as a recognised side effect in the official Summary of Product Characteristics for Rybelsus. Current evidence does not establish a direct pharmacological mechanism by which semaglutide would alter mood, though indirect factors such as blood glucose changes or gastrointestinal symptoms may influence emotional wellbeing.
Monitor your blood glucose levels regularly and keep a diary of any mood symptoms. Discuss any persistent or concerning changes with your GP or diabetes specialist nurse, who can assess whether medication adjustment is needed and screen for other potential causes such as depression or anxiety.
Seek immediate medical attention if you experience thoughts of self-harm or suicide, persistent low mood lasting more than two weeks, severe anxiety interfering with daily life, or frequent symptoms of hypoglycaemia. Call 999 or attend A&E if you feel in immediate danger, or contact the Samaritans on 116 123 for confidential support.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
